{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:50:53Z","timestamp":1782384653339,"version":"3.54.5"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic muscle-invasive bladder cancer carries a poor prognosis despite recent therapeutic advances. Enfortumab vedotin plus pembrolizumab (EVP) is now the standard first-line treatment for metastatic urothelial carcinoma. However, the role of local consolidative treatment after deep systemic response remains undefined. We report the case of a 59-year-old man with de novo metastatic bladder cancer (cT3N1M1) treated with first-line EVP. After 10 cycles, imaging demonstrated a sustained complete metabolic response. Consolidative radical cystoprostatectomy with Bricker diversion confirmed a complete pathological response (ypT0N0M0R0). This case highlights that deferred local consolidative surgery may be considered in carefully selected metastatic patients achieving durable responses to modern systemic therapies.<\/jats:p>","DOI":"10.1093\/jscr\/rjag435","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:40:41Z","timestamp":1779190841000},"source":"Crossref","is-referenced-by-count":0,"title":["Consolidative cystectomy after complete response to enfortumab vedotin plus pembrolizumab in metastatic bladder cancer: a case report"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6296-5077","authenticated-orcid":false,"given":"Romain","family":"Lefranc","sequence":"first","affiliation":[{"name":"Urology Department, CHU de Caen , avenue de la C\u00f4te de Nacre, 14000 Caen ,","place":["France"]},{"name":"Oncology Department, CHU de Caen , avenue de la C\u00f4te de Nacre, 14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Urology Department, CHU de Caen , avenue de la C\u00f4te de Nacre, 14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achraf","family":"Ghorbel","sequence":"additional","affiliation":[{"name":"Oncology Department, CHU de Caen , avenue de la C\u00f4te de Nacre, 14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"L\u00e9ger-Vigot","sequence":"additional","affiliation":[{"name":"Pathology Department, CHU de Caen , avenue de la C\u00f4te de Nacre, 14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Tillou","sequence":"additional","affiliation":[{"name":"Urology Department, CHU de Caen , avenue de la C\u00f4te de Nacre, 14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Waeckel","sequence":"additional","affiliation":[{"name":"Urology Department, CHU de Caen , avenue de la C\u00f4te de Nacre, 14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026062506251692100_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102741","article-title":"French AFU Cancer Committee Guidelines\u2014update 2024\u20132026: muscle-invasive bladder cancer (MIBC)","volume":"34","author":"Roumigui\u00e9","year":"2024","journal-title":"Prog Urol"},{"key":"2026062506251692100_ref2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062506251692100_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Exploratory subgroup analyses of EV-302: enfortumab vedotin plus pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","volume":"10","author":"Heijden","year":"2025","journal-title":"ESMO Open"},{"key":"2026062506251692100_ref4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026062506251692100_ref5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"European Association of Urology guidelines on metastatic urothelial carcinoma: 2021 update","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"2026062506251692100_ref6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","article-title":"The role of surgery in metastatic bladder cancer: a systematic review","volume":"73","author":"Abufaraj","year":"2018","journal-title":"Eur Urol"},{"key":"2026062506251692100_ref7","doi-asserted-by":"publisher","first-page":"162.e11","DOI":"10.1016\/j.urolonc.2024.02.007","article-title":"Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases","volume":"42","author":"Xu","year":"2024","journal-title":"Urol Oncol"},{"key":"2026062506251692100_ref8","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s00345-019-02693-y","article-title":"The role of metastatic burden in cytoreductive\/consolidative radical cystectomy","volume":"37","author":"Li","year":"2019","journal-title":"World J Urol"},{"key":"2026062506251692100_ref9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062506251692100_ref10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk muscle-invasive bladder cancer who are ctDNA-positive after surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol"},{"key":"2026062506251692100_ref11","article-title":"Perioperative enfortumab vedotin plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer: results from the phase III KEYNOTE-905 study","volume-title":"Presented at: European Society for Medical Oncology (ESMO) Congress 2025","author":"Vulsteke"},{"key":"2026062506251692100_ref12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma (CARMENA)","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062506251692100_ref13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate versus deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026062506251692100_ref14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14796694.2025.2482363","article-title":"Role of local consolidative treatment in advanced and metastatic urothelial carcinoma in the era of modern systemic therapies","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol"}],"container-title":["Journal of Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2026\/6\/rjag435\/68610309\/rjag435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jscr\/article-pdf\/2026\/6\/rjag435\/68610309\/rjag435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:25:25Z","timestamp":1782383125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jscr\/article\/doi\/10.1093\/jscr\/rjag435\/8704817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jscr\/rjag435","relation":{},"ISSN":["2042-8812"],"issn-type":[{"value":"2042-8812","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,31]]},"article-number":"rjag435"}}